ArticleInvestigational new drugs2015

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.

Mark J Ratain et al.PubMed ↗Publisher ↗

No numbers read from the abstract.